Ilaris EU approval for CAPS

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

• First drug approved in EU for patients as young as four years old with cryopyrin-associated periodic syndrome (CAPS)
• Approval based on positive data showing Ilaris produced rapid and sustained remission of CAPS symptoms in up to 97% of patients
• Ilaris is a monoclonal antibody that selectively targets and blocks interleukin-1 beta (IL-1ß), the trigger for inflammation and tissue damage in CAPS patients
• Studies ongoing in groups of patients with other diseases involving IL-1ß such as COPD, type 2 diabetes and gout – one of the most painful forms of arthritis

Download the media release
(English, 75 KB)

 

 

Living with Muckle Wells: Aaron Church's story

 

Download the video
(MPG, 2.6 MB)

 

 

Fact sheets (5)

 

 

Additional video (1)

 

 

Animation (1)

 

 

 

The information in the press release and other materials was factually accurate on the date of publication. The press release and other materials remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.